樂普生物－Ｂ
No. 651, Lianheng Road
Minhang District
Shanghai 201612
China
86 21 6768 0899
https://www.lepubiopharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 429
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Zhongjie Pu | Executive Chairman | 無 | 無 | 1963 |
| Dr. Ziye Sui M.D., Ph.D. | CEO & Director | 2.96M | 無 | 1981 |
| Ms. Yunyi Li | CFO & Board Secretary | 無 | 無 | 1980 |
| Dr. Minmin Qin Ph.D. | Chief Technology Officer | 無 | 無 | 1958 |
| Ms. Lixuan Zhao | Supervisor & Investor Relations Director | 無 | 無 | 1992 |
| Ms. Siu Kuen Lai FCIS, FCS | Joint Company Secretary | 無 | 無 | 1976 |
描述
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China.
公司管治
截至 無 止，樂普生物－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
